Skip to content

Study · Observational study · n = 1,157 · 2018

4 results

Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes.

Overbeek JA, Heintjes EM, Huisman EL, Tikkanen CK, van Diermen AW, Penning-van Beest FJA, Herings RMC

Diabetes, obesity & metabolism29 May 2018Cited by 12 (Europe PMC)

PMID29726082 (opens in a new tab)PMCIDPMC6099315 (opens in a new tab)DOI10.1111/dom.13335 (opens in a new tab)PepBankPUB-29726082
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes, HbA1c fell significantly more with liraglutide than with basal insulin supported oral therapy at 12 months.

    In plain wordsIn obese adults with type 2 diabetes, liraglutide lowered HbA1c more than basal insulin after 12 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change from baseline at 12 months
    Study

    n = 1,157

    Comparator
    Basal insulin supported oral therapy (BOT)
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −12.2 mmol/mol
    liraglutide, 12 months
    HbA1c change
    −8.8 mmol/mol
    BOT, 12 months

    Source sentences

    Summary
    From 3 months onwards, glycaemic control improved in both cohorts but improved significantly more with liraglutide than with BOT (12 months: -12.2 mmol/mol vs -8.8 mmol/mol; P = .0053).
    2 context sentences
    Summary · context
    This was a retrospective, propensity score-matched, longitudinal cohort study using real-world data (January 2010 to December 2015) from the Dutch PHARMO Database Network.
    Summary · context
    Adult obese (body mass index [BMI] ≥35 kg/m2 ) patients with T2DM with ≥2 dispensing dates for liraglutide or basal insulin supported oral therapy (BOT) were selected.
  2. 02HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes, weight was significantly lower with liraglutide than with basal insulin supported oral therapy at 12 months.

    In plain wordsIn obese adults with type 2 diabetes, weight was lower with liraglutide than with basal insulin after 12 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight change from baseline at 12 months
    Study

    n = 1,157

    Comparator
    Basal insulin supported oral therapy (BOT)
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Weight change
    −6 kg
    liraglutide, 12 months
    Weight change
    −1.6 kg
    BOT, 12 months

    Source sentences

    Summary
    In addition, weight and BMI were significantly lower for treatments with liraglutide vs BOT (12 months: -6.0 kg vs -1.6 kg and - 2.1 kg/m2 vs -0.5 kg/m2 , respectively; P < .0001 for both).
    2 context sentences
    Summary · context
    This was a retrospective, propensity score-matched, longitudinal cohort study using real-world data (January 2010 to December 2015) from the Dutch PHARMO Database Network.
    Summary · context
    Adult obese (body mass index [BMI] ≥35 kg/m2 ) patients with T2DM with ≥2 dispensing dates for liraglutide or basal insulin supported oral therapy (BOT) were selected.
  3. 03HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes, BMI was significantly lower with liraglutide than with basal insulin supported oral therapy at 12 months.

    In plain wordsIn obese adults with type 2 diabetes, BMI was lower with liraglutide than with basal insulin after 12 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI change from baseline at 12 months
    Study

    n = 1,157

    Comparator
    Basal insulin supported oral therapy (BOT)
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    BMI change
    −2.1 kg/m2
    liraglutide, 12 months
    BMI change
    −0.5 kg/m2
    BOT, 12 months

    Source sentences

    Summary
    In addition, weight and BMI were significantly lower for treatments with liraglutide vs BOT (12 months: -6.0 kg vs -1.6 kg and - 2.1 kg/m2 vs -0.5 kg/m2 , respectively; P < .0001 for both).
    2 context sentences
    Summary · context
    This was a retrospective, propensity score-matched, longitudinal cohort study using real-world data (January 2010 to December 2015) from the Dutch PHARMO Database Network.
    Summary · context
    Adult obese (body mass index [BMI] ≥35 kg/m2 ) patients with T2DM with ≥2 dispensing dates for liraglutide or basal insulin supported oral therapy (BOT) were selected.
  4. 04HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes, changes in cardiovascular risk factors did not differ significantly between liraglutide and basal insulin supported oral therapy.

    In plain wordsIn obese adults with type 2 diabetes, heart risk factors changed about the same with liraglutide and with basal insulin.

    Peptide
    Liraglutide
    Outcome
    No significant changeCardiovascular risk factors
    Study

    n = 1,157

    Comparator
    Basal insulin supported oral therapy (BOT)
    Analysis
    Secondary
    Outcome group
    Cardiometabolic risk factors · Cardiovascular
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    No significant differences were seen in changes in cardiovascular risk factors.
    2 context sentences
    Summary · context
    This was a retrospective, propensity score-matched, longitudinal cohort study using real-world data (January 2010 to December 2015) from the Dutch PHARMO Database Network.
    Summary · context
    Adult obese (body mass index [BMI] ≥35 kg/m2 ) patients with T2DM with ≥2 dispensing dates for liraglutide or basal insulin supported oral therapy (BOT) were selected.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT04529278

Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients

Fondation Hôpital Saint-Josephn = 1818 Jan 2021 to est. 31 Dec 2023

Diabetes Mellitus, Type 2 · Hemodialysis · Obese

Trial pageClinicalTrials.govUpdated 14 Apr 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.